117 related articles for article (PubMed ID: 22188260)
1. Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry.
Wu J; Pungaliya P; Kraynov E; Bates B
Biomarkers; 2012 Mar; 17(2):125-33. PubMed ID: 22188260
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin-c splicing isoform contributes to ovarian cancer progression.
Tilli TM; Franco VF; Robbs BK; Wanderley JL; da Silva FR; de Mello KD; Viola JP; Weber GF; Gimba ER
Mol Cancer Res; 2011 Mar; 9(3):280-93. PubMed ID: 21263033
[TBL] [Abstract][Full Text] [Related]
3. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.
Goparaju CM; Pass HI; Blasberg JD; Hirsch N; Donington JS
J Thorac Oncol; 2010 Oct; 5(10):1516-23. PubMed ID: 20689445
[TBL] [Abstract][Full Text] [Related]
4. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
5. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer.
Chang YS; Kim HJ; Chang J; Ahn CM; Kim SK; Kim SK
Lung Cancer; 2007 Sep; 57(3):373-80. PubMed ID: 17513004
[TBL] [Abstract][Full Text] [Related]
6. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.
Nakamura KD; Tilli TM; Wanderley JL; Palumbo A; Mattos RM; Ferreira AC; Klumb CE; Nasciutti LE; Gimba ER
Tumour Biol; 2016 Feb; 37(2):2655-63. PubMed ID: 26404131
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin as a marker of weight loss in lung cancer.
Karadag F; Gulen ST; Karul AB; Kilicarslan N; Ceylan E; Kuman NK; Cildag O
Scand J Clin Lab Invest; 2011 Dec; 71(8):690-4. PubMed ID: 22017168
[TBL] [Abstract][Full Text] [Related]
9. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways.
Gimba ER; Tilli TM
Cancer Lett; 2013 Apr; 331(1):11-7. PubMed ID: 23246372
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy.
Güttler A; Giebler M; Cuno P; Wichmann H; Keßler J; Ostheimer C; Söling A; Strauss C; Illert J; Kappler M; Vordermark D; Bache M
Radiother Oncol; 2013 Sep; 108(3):535-40. PubMed ID: 23891093
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin-4 and Osteopontin-5 splice variants are expressed in several tumor cell lines.
Silva GR; Mattos DS; Bastos ACF; Viana BPPB; Brum MCM; Ferreira LB; Gimba ERP
Mol Biol Rep; 2020 Oct; 47(10):8339-8345. PubMed ID: 33006711
[TBL] [Abstract][Full Text] [Related]
12. The osteopontin-c splice junction is important for anchorage-independent growth.
Shen H; Weber GF
Mol Carcinog; 2014 Jun; 53(6):480-7. PubMed ID: 23359517
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
Cui R; Takahashi F; Ohashi R; Yoshioka M; Gu T; Tajima K; Unnoura T; Iwakami S; Hirama M; Ishiwata T; Iwase A; Takahashi K
Lung Cancer; 2009 Mar; 63(3):368-74. PubMed ID: 18752867
[TBL] [Abstract][Full Text] [Related]
14. [The expression of galectin-3 and osteopontin in occult metastasis of non-small cell lung cancer].
Liang Y; Li H; Hou SC; Hu B; Miao JB; Li T; You B; Yu LX; Wang L; Chen QR; Chen X
Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(14):1061-3. PubMed ID: 19781269
[TBL] [Abstract][Full Text] [Related]
15. Novel transmembrane GTPase of non-small cell lung cancer identified by mRNA differential display.
Chung JG; Yeh KT; Wu SL; Hsu NY; Chen GW; Yeh YW; Ho HC
Cancer Res; 2001 Dec; 61(24):8873-9. PubMed ID: 11751411
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma.
Lin J; Myers AL; Wang Z; Nancarrow DJ; Ferrer-Torres D; Handlogten A; Leverenz K; Bao J; Thomas DG; Wang TD; Orringer MB; Reddy RM; Chang AC; Beer DG; Lin L
Oncotarget; 2015 Sep; 6(26):22239-57. PubMed ID: 26068949
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving NFATc2-mediated suppression on calcium-induced ROS levels.
Huang J; Hu M; Niu H; Wang J; Si Y; Cheng S; Ding W
BMC Cancer; 2021 Jun; 21(1):750. PubMed ID: 34187410
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis and immunodetection of the bovine milk osteopontin isoforms.
Bissonnette N; Dudemaine PL; Thibault C; Robitaille G
J Dairy Sci; 2012 Feb; 95(2):567-79. PubMed ID: 22281321
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity.
Blasberg JD; Goparaju CM; Pass HI; Donington JS
J Thorac Cardiovasc Surg; 2010 Jun; 139(6):1587-93. PubMed ID: 19818970
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN.
Sarosiek K; Jones E; Chipitsyna G; Al-Zoubi M; Kang C; Saxena S; Gandhi AV; Sendiky J; Yeo CJ; Arafat HA
J Gastrointest Surg; 2015 Apr; 19(4):639-50. PubMed ID: 25583441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
